Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Unusual Machines Inc. Common Stock (UMAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Unusual Machines Inc. Common Stock — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Unusual Machines Inc. Common Stock trades at $17.36 (market cap $971.15M). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 5× Unusual Machines Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Unusual Machines Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Unusual Machines Inc. Common Stock for 0 Days on average.
| TVTX | UMAC | |
|---|---|---|
Market Cap | $4.88B | $971.15M |
Volume | 1,668,577 | 3,714,986 |
Sector | Health | Technology |
52-Week High | $67.52 | $34.06 |
52-Week Low | $26.79 | $7.76 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.01B | $657.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Unusual Machines Inc. Common Stock
Unusual Machines Inc. manufactures and sells drone components and complete drones for consumer, enterprise, and defense markets, operating brands including Fat Shark FPV goggles and the Rotor Riot retail platform, with US-based, NDAA-compliant manufacturing.
Read more on UMAC →
